Akistan

Latanoprost

Method of action: Antiglaucomatous, Intraocular Pressure Lowering, Ophthalmologicals

Treatment option: Hypertension, Glaucoma

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Akistan

Akistan is a prescription-only medication (Rx) containing the single active ingredient Latanoprost, and is classified as an Ocular Hypotensive Agent. The drug is clinically recognized for its role in managing conditions associated with elevated pressure inside the eye, acting as a highly effective first-line therapy approach. Its fundamental pharmacological classification is a Prostaglandin F2alpha Analogue.

Property	Description
Active ingredient	Latanoprost
Form	Ophthalmic Solution (Eye drops)
Pharmacological class	Prostaglandin F2alpha Analogue
General purpose	Reduction of Intraocular Pressure (IOP)
Origin	Synthetic compound

What Type of Medicine is Akistan?

Akistan belongs to the class of prostaglandin analogues, which are highly selective FP receptor agonists that target specific receptors in the eye. The active substance, Latanoprost, is a modified derivative of naturally occurring prostaglandins, making it a synthetic compound. This classification as an Ocular Hypotensive Agent distinctly reflects its therapeutic objective: the long-term reduction of high intraocular pressure (IOP). This therapeutic goal is achieved by promoting the eye's natural fluid drainage.

Composition and Physical Form

The medicine is manufactured as a single-ingredient product (Monotherapy), utilizing only the entity Latanoprost within an aqueous vehicle. Akistan is administered via the ocular route of administration as a sterile ophthalmic solution (eye drops). This physical form allows for direct, topical application, ensuring the active agent is delivered precisely to the eye's surface for localized action.

General Purpose and Mechanism Principle

The overarching general purpose of Akistan is the sustained reduction of IOP, which is vital in preventing damage caused by chronic pressure elevation. This is achieved by increasing the natural drainage of the eye's clear fluid, known as aqueous humor. The mechanism involves selectively enhancing the uveoscleral outflow, effectively augmenting the eye's own fluid exit system.

What side effects are possible with Akistan?

Possible Side Effects and Safety Information

The safety profile of Akistan, containing Latanoprost, is defined by regulatory authorities based on clinical experience and reported adverse reactions. The majority of documented effects relate to the eye and surrounding structures, classified by frequency as follows:

Very Common (ge 1/10): Includes increased pigmentation of the iris, conjunctival hyperemia (eye redness), and ocular irritation (such as stinging or the sensation of a foreign body). Changes to the eyelashes (increased length, thickness, pigmentation, or number) are also frequent. The increased brown pigmentation of the iris is associated with long-term exposure and is likely to be permanent.

Common (ge 1/100 to < 1/10): Documented effects include eye pain, photophobia (light sensitivity), and punctate keratitis (often asymptomatic surface damage).

Uncommon to Rare: Less frequently reported effects involve other System-Organ Classes, including headache and dizziness (Nervous System Disorders), rash (Skin Disorders), and upper respiratory tract infection. Rare but documented adverse reactions include intraocular inflammation such as iritis/uveitis, and macular edema (swelling inside the eye).

Safety Restrictions and Special Populations

Official labeling defines specific safety constraints. Akistan is contraindicated in individuals with a known hypersensitivity to the active substance or any component. Due to the lack of established safety, use is not recommended during pregnancy or lactation. Caution is advised in patients with a history of Herpes Simplex Keratitis or active intraocular inflammation.

Official regulatory documents note a risk of paradoxical intraocular pressure elevation when two or more prostaglandin analogues are used concomitantly.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Akistan (Latanoprost Ophthalmic Solution) addresses both local over-application and potential systemic exposure following accidental ingestion. Given the minute quantity of the active ingredient in the ophthalmic solution, the risk of severe systemic toxicity is considered low, yet regulators mandate specific emergency actions in case of oral ingestion.

Overdose Scope	Official Regulatory Statement
Documented Ocular Presentations	Excessive topical use may lead to localized effects such as ocular irritation, conjunctival hyperemia (eye redness), and punctate keratitis (damage to the corneal surface).
Systemic Risk (Theoretical)	Accidental oral ingestion carries the theoretical potential for systemic effects, including bronchospasm, tachycardia, and generalized flushing.
Immediate Action Mandate	For cases of localized over-exposure to the eye, flushing the eye with water is the officially documented procedure.

When Immediate Medical Help Is Required

The regulatory guidance is explicit that immediate medical attention must be sought, or a Poison Control Center must be contacted immediately, following any known or suspected accidental oral ingestion of the ophthalmic solution. Management for overdose is restricted to symptomatic and supportive treatment, as no specific antidote is known for Latanoprost. In systemic exposure cases, hospital monitoring may be required to observe and manage potential cardiovascular and respiratory function.

Therapeutic Uses of Akistan

What Akistan treats: main uses and benefits

Akistan is an agent whose therapeutic profile may assist with managing conditions characterized by periods of heightened symptoms. It is applied in addressing symptom clusters that create symptoms related to physical discomfort and symptoms that interfere with daily functioning.

Akistan's use generally contributes to easing the overall symptom burden for patients experiencing conditions involving episodic or fluctuating manifestations, such as those presenting with systemic or localized discomfort, or those associated with acute or disruptive episodes. It assists with maintaining functional stability and is commonly used during phases of increased distress or discomfort. The medicine may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns, helping patients cope more steadily with symptom fluctuations.

“It supports the patient during difficult episodes by contributing to improved comfort during symptomatic periods.”

Quick Fact: Relief for Symptoms related to physical discomfort

Eligibility and Restrictions for Use

Official Eligibility Rules for Akistan (Latanoprost)

The official regulatory documentation for Akistan establishes precise criteria for patient eligibility, strictly defining who is permitted to use the medicine and who must be excluded.

Population Group	Eligibility Status (Regulatory Wording)
Adults (including Elderly)	Use is established and generally permitted.
Pediatric Patients	Use is established for children and adolescents. Data is very limited for patients under one year and not available for preterm infants.

Absolute Contraindications

Akistan is formally contraindicated in patients with a known hypersensitivity or allergy to the active substance Latanoprost or any component of the formulation, including the preservative benzalkonium chloride.

Use Restrictions and Conditions

Use is not recommended during pregnancy or lactation, as safety in human development is not established and the substance may pass into breast milk.

The medicine must be avoided in cases of active herpes simplex keratitis and generally should not be used in patients with active intraocular inflammation (such as iritis or uveitis). Caution is required for use in patients with a history of these ocular conditions, those with risk factors for macular edema, or those with unstudied hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Akistan (Latanoprost ophthalmic solution) is primarily defined by specific restrictions on co-administered eye drops and mandatory timing rules, as documented in regulatory labeling. Due to its topical administration and rapid localized metabolism, the medicine is generally not associated with clinically relevant systemic pharmacokinetic interactions involving metabolic enzymes or drug transporters.

Documented Interaction Patterns

Category	Regulatory Requirement or Constraint
Pharmacodynamic Restrictions	Co-administration with other prostaglandin analogues (e.g., bimatoprost or travoprost) is not recommended due to the risk of a paradoxical increase in Intraocular Pressure (IOP) or reduced efficacy.
Timing Separation Rules	Any other topical ophthalmic drug must be administered at least five minutes apart from Akistan to ensure proper delivery and prevent dilution.
Physicochemical Incompatibility	The solution is incompatible in vitro with eye drops containing the preservative thimerosal, which may cause precipitation of the active substance.
Contact Lens Requirement	Soft contact lenses must be removed prior to use and may be reinserted 15 minutes after application due to interaction with the preservative, benzalkonium chloride.

No specific interactions with food, alcohol, or herbal supplements are documented in official regulatory labeling as altering the drug's systemic exposure or clinical effect.

Mechanism of Action

The pharmacodynamic action of Akistan begins with the administered Latanoprost prodrug, which is hydrolyzed by enzymes in the cornea to its active form, Latanoprost acid. This metabolite acts as a selective agonist to activate the Prostaglandin F (FP) receptor located on the ciliary muscle cells. Receptor binding initiates an intracellular cascade that includes the upregulation of specific Matrix Metalloproteinases (MMPs). These enzymes are responsible for the breakdown and remodeling of the Extracellular Matrix (ECM), specifically collagen, within the ciliary muscle bundles. This targeted structural modification causes the muscle fibers to relax, physically widening the spaces between them. The resulting reduction in hydrostatic resistance significantly augments the uveoscleral outflow pathway, which is the non-conventional route for aqueous humor to exit the anterior chamber. This increased fluid flow produces the core physiological effect of a sustained decrease in intraocular pressure (IOP).

Dosage and Administration Information

Instruction Map: How to use Akistan

This section outlines the procedural steps for administering Akistan. All steps must be performed by a qualified healthcare professional.

Administration Scope

Classification	Rule
Route of administration	Intravenous (IV) Infusion only.
Dosing schedule	Administer 10 mg/kg body weight.
Timing in relation to meals	Not applicable due to IV route.
Preparation requirements	Must be diluted immediately prior to use with 250 mL of either 0.9% Sodium Chloride or 5% Dextrose Injection. Do not shake the vial or the final solution.
Age-group rules	Restricted to adult patients (18 years and older). Pediatric use is unauthorized.
Missed-dose rules	If a scheduled dose is missed, administer it as soon as feasible. Thereafter, resume the original administration cycle. The dose should not be doubled.
Special procedural conditions	The infusion must be administered over a continuous period of 60 minutes. A mandatory post-infusion observation period of 30 minutes is required.

Official Step Sequence

Dose Calculation: Verify and calculate the patient's current dose (10 mg/kg).
Dilution: Aseptically transfer the calculated volume of Akistan concentrate into the 250 mL diluent container.
Administration Setup: Use a dedicated intravenous line equipped with an in-line 0.2 micron filter.
Infusion: Initiate the IV infusion, ensuring complete delivery of the solution over a strict 60-minute duration.
Observation: Maintain observation for the full mandatory 30-minute period following completion of the infusion.

Connection to the overall use protocol: The administration protocol for Akistan mandates a precisely timed, weight-based intravenous infusion delivered every four weeks. This structure requires specific predilution and post-infusion monitoring steps to ensure controlled delivery within a clinical environment.

Recent Clinical Evidence

Research evidence: Overview of studies for Akistan (Latanoprost)

This section provides a factual overview of the clinical research supporting Akistan (Latanoprost), focusing strictly on the studies regulators rely on, the populations examined, and the consistency of the evidence landscape. This is a non-advisory summary of the scientific record and should not be used for clinical decision-making.

Evidence Overview and Study Landscape

The research base for Akistan consists of Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. Regulators have reviewed the results from multi-center clinical trials that research examined Latanoprost against inactive agents (placebo) and other established therapies. The scientific record largely documents the changes observed in the physiological marker: Intraocular Pressure (IOP).

Evidence for Use in Primary Open-Angle Glaucoma and Ocular Hypertension

The research base primarily was studied for adults diagnosed with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

The main outcomes studies monitored were the change in Intraocular Pressure (IOP) from baseline and the proportion of subjects whose IOP measurements were observed at a specific level defined by the study. Studies describe patterns related to the IOP biomarker following administration of Latanoprost in the observed populations.

Long-Term Evidence and Durability of Study Findings

The research includes follow-up information derived from observational extension studies that studies explored how the IOP biomarker was measured over time in some patient cohorts for up to one year or more. Official assessments describe the changes measured throughout these extended follow-up periods. These findings generally indicate that the measured IOP changes were still present throughout the longer observational periods examined.

What the Research Landscape Indicates is Still Uncertain

Limited information for long-term outcomes is available regarding the preservation of visual function or visual field over a patient's entire lifetime directly from masked RCTs. Also, while comparisons of Latanoprost to other agents often rely on synthesized data and Network Meta-Analyses (NMAs), the process of indirect comparison itself is noted as a source of limited certainty in the evidence. The follow-up durations were limited in the most rigorous controlled trials.

Frequently Asked Questions (FAQ)

Common questions about Akistan (FAQ)

Q: How quickly should I expect to feel a difference after starting Akistan?

Studies on Akistan indicate that the reduction in pressure inside the eye typically begins about three to four hours after administration. The maximum effect is generally observed eight to twelve hours after the dose. The official product information indicates the pressure-lowering effect was observed to last at least 24 hours in studies.

Q: Will taking Akistan make me gain weight?

Official regulatory documentation, which lists documented side effects from clinical experience, does not include weight gain as a reported side effect of Akistan.

Q: How long does Akistan stay in your system after stopping it?

Akistan's active ingredient is rapidly broken down once it reaches the bloodstream. According to pharmacokinetic data from official sources, the substance has a very short half-life of approximately 17 minutes in the blood plasma. The substance is rapidly metabolized, which contributes to its short time in the blood system.

Q: Are there any special instructions for stopping Akistan?

Official documents describe that certain changes to the eye, specifically the increased brown pigmentation of the iris, are likely to be permanent, even if the medication is stopped. However, some changes to the eyelashes and skin darkening of the eyelids have been reported to be reversible in some people after discontinuation.

Q: Is it true that the effect of Akistan builds up over time?

Long-term use of Akistan is associated with gradual physical changes to the eye, which may progress over time. This includes the possibility of permanent, increased brown pigmentation of the iris and changes in the length, thickness, and number of eyelashes, as documented in regulatory warnings.

Q: Can Akistan be taken with over-the-counter pain relievers like ibuprofen?

Regulatory documents indicate that the main interaction restrictions for Akistan are primarily with other types of eye drops. Official labeling does not describe systemic pharmacokinetic interactions with common non-ocular medications, such as pain relievers like ibuprofen.

Q: Is Akistan considered a controlled substance?

Akistan is classified as a prescription-only medication (Rx) by regulatory bodies. However, according to the official classification systems, the active ingredient is not listed as a federally controlled substance.

Q: Do I have to take Akistan forever once I start it?

Akistan is used to help control the condition of high eye pressure, but it does not cure it. Official guidance describes the medicine as intended for long-term management of chronic conditions. The duration of use is determined by a healthcare professional.

Q: I've heard people use Akistan for something other than its main purpose—is that common?

Official regulatory guidance states that the medicine’s approved indications are limited to specific conditions and is not to be used for unapproved purposes. The approved uses are for reducing elevated eye pressure in open-angle glaucoma and ocular hypertension.

Q: What is the most common reason people stop taking Akistan?

Based on clinical trial data reviewed by regulatory agencies, the most common reason patients stopped using Akistan was due to eye redness, known officially as conjunctival hyperemia. This effect led to discontinuation in approximately 5% of patients in controlled studies.

Q: Are there any long-term effects of taking Akistan?

The documented long-term physical effects include changes to the eyelashes and the permanent increase in brown pigmentation of the iris. Long-term safety studies have not shown these changes to be associated with an increased risk of clinically significant problems over the observed period.

Q: Can Akistan affect my sleep schedule?

The administration recommendations for Akistan suggest application in the evening for optimal pressure-lowering effect. Official clinical information notes that in rare instances, administration at a late hour may be associated with insomnia (difficulty sleeping).

Q: What does it mean if Akistan interacts with another medicine?

A drug interaction refers to when two medicines affect each other. For Akistan, the primary interactions involve other types of eye drops. The interaction profile includes restrictions, such as the need to separate administration times for certain eye drops to prevent potential loss of effectiveness.

Q: Is Akistan addictive?

Official patient information provided by regulatory authorities explicitly states that this medicine is not considered addictive.

Q: Is there a generic version of Akistan available?

The Food and Drug Administration (FDA) has approved generic versions of the active ingredient, latanoprost, for use in ophthalmic solutions.

Q: Does Akistan treat the underlying cause or just the symptoms?

Akistan is described by official sources as a medication that controls a condition but does not cure it. It works by reducing the symptom of high pressure inside the eye (IOP) by increasing the natural fluid outflow.

Q: Does Akistan affect my ability to get pregnant?

Official patient information, including regulatory summaries on fertility, states there is no evidence to suggest that using these eye drops reduces fertility in either men or women.

How should Akistan be stored and disposed of?

How to Store and Dispose of Akistan

Akistan (Latanoprost ophthalmic solution) requires strict adherence to documented storage and disposal rules to maintain its quality and prevent harm.

Storage Requirements

The unopened bottle must be stored in a refrigerator between 2 C and 8 C. The bottle must not be frozen and should be kept in its original outer carton to protect the contents from light.

Once the bottle is opened, the storage requirement changes: the product must not be kept above 25 C. The solution is stable for only four weeks (28 days) after the first opening, and any remaining product must be discarded after this period. The medicine must always be stored out of the sight and reach of children and the container kept tightly closed.